305 related articles for article (PubMed ID: 12042864)
1. Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affinity.
Maynard JA; Maassen CB; Leppla SH; Brasky K; Patterson JL; Iverson BL; Georgiou G
Nat Biotechnol; 2002 Jun; 20(6):597-601. PubMed ID: 12042864
[TBL] [Abstract][Full Text] [Related]
2. Passive vaccination with a human monoclonal antibody: generation of antibodies and studies for efficacy in Bacillus anthracis infections.
vor dem Esche U; Huber M; Zgaga-Griesz A; Grunow R; Beyer W; Hahn U; Bessler WG
Immunobiology; 2011 Jul; 216(7):847-53. PubMed ID: 21397977
[TBL] [Abstract][Full Text] [Related]
3. High-affinity, human antibody-like antibody fragment (single-chain variable fragment) neutralizing the lethal factor (LF) of Bacillus anthracis by inhibiting protective antigen-LF complex formation.
Pelat T; Hust M; Laffly E; Condemine F; Bottex C; Vidal D; Lefranc MP; Dübel S; Thullier P
Antimicrob Agents Chemother; 2007 Aug; 51(8):2758-64. PubMed ID: 17517846
[TBL] [Abstract][Full Text] [Related]
4. Selection of human antibodies against cell surface-associated oligomeric anthrax protective antigen.
Steiniger SC; Altobell LJ; Zhou B; Janda KD
Mol Immunol; 2007 Apr; 44(10):2749-55. PubMed ID: 17210180
[TBL] [Abstract][Full Text] [Related]
5. [Immunogenicity of the recombinant Bacillus strains with cloned gene of biosynthesis of protective antigen against Bacillus anthracis].
Mikshis NI; Kudriavtseva OM; Bolothikova MF; Shulepov DV; Novikova LV; Popov IuA; Shchukovskaia TN; Drozdov IG; Kutyrev VV
Mol Gen Mikrobiol Virusol; 2007; (3):15-21. PubMed ID: 17886469
[TBL] [Abstract][Full Text] [Related]
6. Anthrax capsule vaccine protects against experimental infection.
Chabot DJ; Scorpio A; Tobery SA; Little SF; Norris SL; Friedlander AM
Vaccine; 2004 Nov; 23(1):43-7. PubMed ID: 15519706
[TBL] [Abstract][Full Text] [Related]
7. Passive immunotherapy for anthrax toxin mediated by an adenovirus expressing an anti-protective antigen single-chain antibody.
Kasuya K; Boyer JL; Tan Y; Alipui DO; Hackett NR; Crystal RG
Mol Ther; 2005 Feb; 11(2):237-44. PubMed ID: 15668135
[TBL] [Abstract][Full Text] [Related]
8. Microbiology. A binding contract for anthrax.
Bull JJ; Parrish CR
Science; 2002 Jul; 297(5579):201-2. PubMed ID: 12114612
[No Abstract] [Full Text] [Related]
9. Identification and characterization of immunodominant B-cell epitope of the C-terminus of protective antigen of Bacillus anthracis.
Kaur M; Chug H; Singh H; Chandra S; Mishra M; Sharma M; Bhatnagar R
Mol Immunol; 2009 Jun; 46(10):2107-15. PubMed ID: 19356802
[TBL] [Abstract][Full Text] [Related]
10. An intranasal vaccine targeting both the Bacillus anthracis toxin and bacterium provides protection against aerosol spore challenge in rabbits.
Wimer-Mackin S; Hinchcliffe M; Petrie CR; Warwood SJ; Tino WT; Williams MS; Stenz JP; Cheff A; Richardson C
Vaccine; 2006 May; 24(18):3953-63. PubMed ID: 16530302
[TBL] [Abstract][Full Text] [Related]
11. [Monoclonal antibodies to B.anthracis protective antigen are capable to neutralize and to enhance the anthrax lethal toxin action in vitro].
Belova EV; Dubileĭ SA; Kravchenko TB; Kolesnikov AV; Zakharova MIu; Shemiakin IG
Mol Gen Mikrobiol Virusol; 2004; (3):21-6. PubMed ID: 15354937
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of anthrax toxins with a bispecific monoclonal antibody that cross reacts with edema factor as well as lethal factor of Bacillus anthracis.
Kulshreshtha P; Bhatnagar R
Mol Immunol; 2011 Sep; 48(15-16):1958-65. PubMed ID: 21704379
[TBL] [Abstract][Full Text] [Related]
13. Human-derived, plant-produced monoclonal antibody for the treatment of anthrax.
Hull AK; Criscuolo CJ; Mett V; Groen H; Steeman W; Westra H; Chapman G; Legutki B; Baillie L; Yusibov V
Vaccine; 2005 Mar; 23(17-18):2082-6. PubMed ID: 15755575
[TBL] [Abstract][Full Text] [Related]
14. Human monoclonal anti-protective antigen antibody for the low-dose post-exposure prophylaxis and treatment of Anthrax.
Tang Q; Xiong S; Liang X; Kuai X; Wang Y; Wang C; Feng Z; Zhu J
BMC Infect Dis; 2018 Dec; 18(1):640. PubMed ID: 30526504
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of non-toxic deletion mutants of protective antigen from Bacillus anthracis.
Rhie GE; Park YM; Han JS; Yu JY; Seong WK; Oh HB
FEMS Immunol Med Microbiol; 2005 Aug; 45(2):341-7. PubMed ID: 16019195
[TBL] [Abstract][Full Text] [Related]
16. Investigation of a panel of monoclonal antibodies and polyclonal sera against anthrax toxins resulted in identification of an anti-lethal factor antibody with disease-enhancing characteristics.
Kulshreshtha P; Tiwari A; Priyanka ; Joon S; Sinha S; Bhatnagar R
Mol Immunol; 2015 Dec; 68(2 Pt A):185-93. PubMed ID: 26364143
[TBL] [Abstract][Full Text] [Related]
17. The detection of protective antigen (PA) associated with spores of Bacillus anthracis and the effects of anti-PA antibodies on spore germination and macrophage interactions.
Cote CK; Rossi CA; Kang AS; Morrow PR; Lee JS; Welkos SL
Microb Pathog; 2005; 38(5-6):209-25. PubMed ID: 15925272
[TBL] [Abstract][Full Text] [Related]
18. Catalytically inactive anthrax toxin(s) are potential prophylactic agents.
Gupta M; Alam S; Bhatnagar R
Vaccine; 2007 Dec; 25(50):8410-9. PubMed ID: 17980467
[TBL] [Abstract][Full Text] [Related]
19. Selection of a macaque Fab with framework regions like those in humans, high affinity, and ability to neutralize the protective antigen (PA) of Bacillus anthracis by binding to the segment of PA between residues 686 and 694.
Laffly E; Danjou L; Condemine F; Vidal D; Drouet E; Lefranc MP; Bottex C; Thullier P
Antimicrob Agents Chemother; 2005 Aug; 49(8):3414-20. PubMed ID: 16048955
[TBL] [Abstract][Full Text] [Related]
20. Humanization of a highly stable single-chain antibody by structure-based antigen-binding site grafting.
Villani ME; Morea V; Consalvi V; Chiaraluce R; Desiderio A; Benvenuto E; Donini M
Mol Immunol; 2008 May; 45(9):2474-85. PubMed ID: 18313757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
